about
First-line therapy for chronic graft-versus-host disease that includes low-dose methotrexate is associated with a high response rate.Prolonged thrombocytopenia following allogeneic hematopoietic stem cell transplantation and its association with a reduction in ploidy and an immaturation of megakaryocytes.Association between an impaired bone marrow vascular microenvironment and prolonged isolated thrombocytopenia after allogeneic hematopoietic stem cell transplantation.Immunosuppressive treatment combined with nucleoside analog is superior to nucleoside analog only in the treatment of severe thrombocytopenia in patients with cirrhosis associated with hepatitis B in China: A multicenter, observational study.Adipose-Derived Mesenchymal Stem Cells (ADSCs) With the Potential to Ameliorate Platelet Recovery, Enhance Megakaryopoiesis, and Inhibit Apoptosis of Bone Marrow Cells in a Mouse Model of Radiation-Induced Thrombocytopenia.Recruitment of CD8(+) T cells into bone marrow might explain the suppression of megakaryocyte apoptosis through high expression of CX3CR1(+) in prolonged isolated thrombocytopenia after allogeneic hematopoietic stem cell transplantation.The incidence, risk factors, and outcomes of primary poor graft function after unmanipulated haploidentical stem cell transplantation.Helicobacter pylori infection influences the severity of thrombocytopenia and its treatment response in chronic hepatitis B patients with compensatory cirrhosis: A multicenter, observational study.Desialylation is associated with apoptosis and phagocytosis of platelets in patients with prolonged isolated thrombocytopenia after allo-HSCT.Characterization of thrombopoietin kinetics within 60 days after allogeneic hematopoietic stem cell transplantation and its correlation with megakaryocyte ploidy distribution.Increased prostacyclin levels inhibit the aggregation and activation of platelets via the PI3K-AKT pathway in prolonged isolated thrombocytopenia after allogeneic hematopoietic stem cell transplantation.Clinical characteristics and risk factors of Intracranial hemorrhage in patients following allogeneic hematopoietic stem cell transplantation.Donor-Specific Anti-Human Leukocyte Antigen Antibodies Predict Prolonged Isolated Thrombocytopenia and Inferior Outcomes of Haploidentical Hematopoietic Stem Cell Transplantation.Improving cytomegalovirus-specific T cell reconstitution after haploidentical stem cell transplantationClinical features and treatment outcome in newly diagnosed Chinese patients with multiple myeloma: results of a multicenter analysis.Multicenter phase II study of a combination of cyclosporine a, methotrexate and mycophenolate mofetil for GVHD prophylaxis: results of the Chinese Bone Marrow Transplant Cooperative Group (CBMTCG).Ceruloplasmin is a potential biomarker for aGvHD following allogeneic hematopoietic stem cell transplantationHepatocyte growth factor gene-modified adipose-derived mesenchymal stem cells ameliorate radiation induced liver damage in a rat model.Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina.HLA and KIR genotyping correlates with relapse after T-cell-replete haploidentical transplantation in chronic myeloid leukaemia patients.Higher frequency of regulatory T cells in granulocyte colony-stimulating factor (G-CSF)-primed bone marrow grafts compared with G-CSF-primed peripheral blood grafts.Donor-specific anti-human leukocyte antigen antibodies were associated with primary graft failure after unmanipulated haploidentical blood and marrow transplantation: a prospective study with randomly assigned training and validation setsAllogeneic hematopoietic stem cell transplantation in China: where we are and where to go.Administration of imatinib after allogeneic hematopoietic stem cell transplantation may improve disease-free survival for patients with Philadelphia chromosome-positive acute lymphobla stic leukemia.Differential impact of two doses of antithymocyte globulin conditioning on lymphocyte recovery upon haploidentical hematopoietic stem cell transplantationCombination of White Blood Cell Count at Presentation With Molecular Response at 3 Months Better Predicts Deep Molecular Responses to Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients.Efficacy and Safety of Bortezomib in Multiple Myeloma Patients with Hepatitis B: A Multicenter Retrospective Study.Current status of haploidentical stem cell transplantation for leukemia.Increased reactive oxygen species and exhaustion of quiescent CD34-positive bone marrow cells may contribute to poor graft function after allotransplants.Treatment outcomes in relapsed acute promyelocytic leukemia patients initially treated with all-trans retinoic acid and arsenic compound-based combined therapies.miR-153-3p, a new bio-target, is involved in the pathogenesis of acute graft-versus-host disease via inhibition of indoleamine- 2,3-dioxygenase.The clinical value of the quantitative detection of four cancer-testis antigen genes in multiple myeloma.Unmanipulated HLA-mismatched/haploidentical blood and marrow hematopoietic stem cell transplantation.Use of G-CSF-stimulated marrow in allogeneic hematopoietic stem cell transplantation settings: a comprehensive review.Conflicting impact of alloreactive NK cells on transplantation outcomes after haploidentical transplantation: do the reconstitution kinetics of natural killer cells create these differences?Immunomodulatory strategies for relapse after haploidentical hematopoietic stem cell transplantation in hematologic malignancy patients.Haploidentical hematopoietic stem cell transplantation with unmanipulated granulocyte colony stimulating factor mobilized marrow and blood grafts.Haploidentical bone marrow transplantation without T-cell depletion.Immune reconstitution after haploidentical hematopoietic stem cell transplantation.Haploidentical SCT: the mechanisms underlying the crossing of HLA barriers.
P50
Q33383699-9BBFB91D-432F-4F36-84DC-DCD81786B15FQ33391947-64C2B840-BD45-4C08-816E-8D7BAF35FC40Q33415033-DE8B1893-2D0B-46F8-AC95-FDEC182B9EFBQ33418708-EC48C6B7-C1DC-4675-8A86-35FB4F76C1CEQ33422819-37EFB54D-1772-4EAF-A7C9-536DFF43A8AEQ33424130-F25ACA0E-5B83-4171-AC46-FDB3DEBC423BQ33424223-4060F2B7-7F10-40A7-8795-8ED2F69A7CD7Q33425621-66FEAC3D-A0E9-4B9F-852D-F8AB23090D8DQ33427006-0C8C4849-27F5-4700-938B-2397C4494C2DQ33427735-FB0E65BB-7A9D-4EBF-BB1F-ED8B306F98A3Q33430284-4C0425F0-07F4-4FC3-88C0-AE09128DA052Q33434313-7D34E92C-ADB3-4E53-832A-046503A1C117Q33441698-1E0C6A3F-8A0F-424E-8BC2-BC0A0CC37095Q33597783-166AB9BB-5142-4B21-87EA-E97CFE6528CCQ34448995-A791AAB7-80CC-45BC-BC8E-F6F4DE5A53E8Q34544439-BCD12552-9024-4BE7-91C8-959CABECFBF4Q34626032-1A6E28DB-D18D-44C2-86A8-7B30DC6C85C0Q34689652-71802638-E8BF-4274-999D-064F8258A18AQ35560018-C8CF6401-012D-493C-BBCB-C693C8ABD4E0Q35678422-EEA2A3CD-416A-422F-875C-F0770FE79E56Q35814424-8CD02C8E-27B7-4E06-9959-E3C09609E74BQ35834570-B2644631-D812-47A8-9E6A-990EED13579CQ35965199-11AE91C1-2B72-4E4C-AB83-B78C9F6A08EFQ36123315-30BDE3CA-FCB8-4EC1-BC44-2687953461A8Q36416597-AE09BC91-4AB7-47B4-8A99-968699693174Q36478229-8DCAC8F7-2F13-4E28-826D-8EC977A19E9AQ36705558-DA697B1B-2C2B-41FE-9FC7-25099D373C67Q37088557-54AF8120-C9C3-4C31-A83A-E78508035BE6Q37327622-50012A0C-605E-439C-BFDF-F102577A0683Q37388701-CEBC6D60-A455-4BEE-BDED-80DD124ADCD8Q37565461-B0BBC237-50B5-454A-AA9B-81C043B8FB8EQ37580157-2E6CA6B0-AA41-417C-98BF-183AF864D5A9Q37715061-F0F738BB-D92A-456F-B4C1-67DA5FD90C72Q37772229-677FD818-FB01-4FA2-9014-34071D936D7BQ37894269-42A6FE5B-7F77-4573-A6B8-55F2BAE8956AQ37933828-A3ACFCB0-5183-497F-B498-E2BE41B517F8Q38037328-5D7AD8EC-3C48-4D78-B468-4776C966D8DFQ38064623-A4D2F410-A06C-42CC-8790-C11523597CDEQ38169432-687184E6-4907-45F2-9332-8273833B6B5DQ38190856-26AF7A95-E4D3-4F39-B496-4991398655E9
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Xiao-Jun Huang
@ast
Xiao-Jun Huang
@en
Xiao-Jun Huang
@es
Xiao-Jun Huang
@nl
type
label
Xiao-Jun Huang
@ast
Xiao-Jun Huang
@en
Xiao-Jun Huang
@es
Xiao-Jun Huang
@nl
prefLabel
Xiao-Jun Huang
@ast
Xiao-Jun Huang
@en
Xiao-Jun Huang
@es
Xiao-Jun Huang
@nl
P106
P31
P496
0000-0002-2145-6643